20th April 2022 | Pharma Updates
Comera & Intas Pharma partnered to develop bio-innovative biologic therapeutics
Intas Pharmaceuticals established a research partnership with Comera Life Sciences, to develop a new generation of bio-innovative biologic medicines that would improve patient access, safety, and convenience.
J&J cancels its COVID vaccine sales prediction and lowers its profitforecast
Due to a global supply surplus and market uncertainties, Johnson & Johnson halted its sales projection for the COVID-19 vaccine and lowered its adjusted profit forecast, sending the drugmaker’s stock down roughly 3%.
Taking a leap into the future of Indian pharmaceuticals
The Indian pharmaceutical sector ranks third in the world in terms of volume output and supplies 20% of global demand in the generic market.
In Q4, pharma firms' profitability likely to be impacted by cost pressure
The local market is expected to help Indian pharmaceutical companies develop somewhat in the fourth quarter of the financial year 2021-22 (Q4FY22).
Phase 3 clinical trials of the breast cancer therapy 'Tucatinib' approved in South Korea
Korea will conduct phase 3 clinical trials of a new breast cancer medication that has been licenced in the US and Europe. The clinical trial is expected to be supplied in Korea because some Korean patients will be involved.
DSE index is falling due to a lack of buyers
Square Pharmaceuticals and Beximco Ltd have become two of the most popular stocks on the market. The investors’ focus was mostly on paper and printing, as well as pharmaceuticals and chemicals.
Kite's new state-of-the-art CAR T-Cell Therapy Manufacturing Facility received FDA approval
US Food and Drug Administration (FDA) has approved commercial production at Kite Pharma’s new CAR T-cell treatment manufacturing plant in Frederick, Maryland.